DODuriye Ozturk

Duriye Ozturk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Duriye Ozturk has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predicting osteoradionecrosis in nasopharyngeal carcinoma: The role of the GLUCAR index

    by Efsun Somay, Erkan Topkan, Sibel Bascil, Sukran Senyurek, Duriye Ozturk, Nilufer Kılıc Durankuş, Ugur Selek

  • Open Access

    The HARP (Hemoglobin–Albumin–C-Reactive Protein) Index: A Biologically Designed Composite Biomarker for Continuous Prognostic Modeling in Locally Advanced Nasopharyngeal Carcinoma

    by Erkan Topkan, Efsun Somay, Sibel Bascil, Duriye Ozturk, Ugur Selek

    Background/Objectives: To evaluate the prognostic significance of the novel hemoglobin–albumin–C-reactive protein (HARP) index in patients with locally advanced nasopharyngeal carcinoma (LANPC) treated with definitive concurrent chemoradiotherapy (CCRT). Methods: This retrospective study included 248 patients with LANPC treated with definitive CCRT between 2011 and 2020. The HARP index [hemoglobin × (albumin ÷ C-reactive protein)] was calculated using pretreatment laboratory values. Prognostic associations between HARP and survival outcomes were evaluated using continuous and categorical Cox regression analyses, restricted cubic spline modeling, receiver operating characteristic analyses, and bootstrap-based internal validation. Results: Lower pretreatment HARP values were independently associated with inferior progression-free survival (PFS) and overall survival (OS). In continuous Cox analyses, increasing HARP values were associated with reduced risks of mortality and disease progression (both p < 0.001). ROC analysis identified 3.2 as the exploratory cut-off value for clinical stratification. Patients with HARP ≥ 3.2 (n = 112) had significantly better outcomes than those with HARP < 3.2 (n = 136). Median PFS and OS were not reached in the high-HARP group, whereas they were 47.0 and 72.0 months, respectively, in the low-HARP group. Low HARP values were associated with inferior PFS (HR, 3.86; p < 0.001) and OS (HR, 3.06; p < 0.001). Bootstrap internal validation demonstrated stable model discrimination with minimal optimism. Conclusions: The novel HARP index is an independently associated and internally validated prognostic biomarker in patients with LANPC treated with definitive CCRT. HARP may provide a practical tool for improved risk stratification, pending prospective external validation.

  • Open Access

    Tissue Resilience in Radiation-Induced Injury: A Hypothesis-Generating Review of Heat Shock Protein 27 in Osteoradionecrosis of the Jaw

    by Erkan Topkan, Doga Topkan, Efsun Somay, Duriye Ozturk, Sibel Bascil, Ugur Selek

    Osteoradionecrosis of the jaw (ORNJ) remains one of the most severe late complications of head and neck radiotherapy. Current evidence suggests that ORNJ is a progressive and biologically heterogeneous disorder driven by microvascular injury, chronic hypoxia, oxidative stress, fibro-atrophic remodeling, impaired bone turnover, immune dysregulation, and systemic susceptibility factors. Within this complex pathogenic network, heat shock protein 27 (HSP27) emerges as a biologically plausible but unexplored mediator. HSP27 regulates multiple stress-response pathways, including redox homeostasis, cytoskeletal stabilization, endothelial protection, apoptosis control, fibroblast activation, and osteoblast–osteoclast function, all of which overlap with key mechanisms implicated in ORNJ. However, no studies have directly investigated HSP27 expression, activation, or functional significance in irradiated mandibular tissues or ORNJ-specific cohorts. This review summarizes current knowledge of ORNJ pathobiology, examines potential mechanistic links with HSP27, and outlines future research priorities involving biomarker development, tissue-level characterization, preclinical modeling, and therapeutic targeting. Integrating HSP27 into ORNJ research may improve understanding of pathogenesis, risk stratification, and the development of novel preventive and therapeutic strategies.

  • Open Access

    Comparative Prognostic Performance of CARWL and Naples Prognostic Score in Stage IIIC Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy

    by Erkan Topkan, Duriye Ozturk, Ugur Selek

    Background: Prognostic stratification remains challenging in patients with stage IIIC non-small cell lung cancer (NSCLC) treated with definitive chemoradiotherapy (CCRT), and the relative performance of host-related prognostic indices in this setting is unclear. The CARWL (C-reactive Protein, Albumin, and Recent Weight Loss) score and the Naples prognostic score (NPS) have each been proposed as prognostic tools, but direct comparisons are lacking. This study compared their prognostic performance. Methods: We retrospectively analyzed 795 patients with stage IIIC NSCLC treated with CCRT between 2010 and 2020. Patients were stratified into three prognostic groups according to CARWL and NPS. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and locoregional PFS (LRPFS) were secondary endpoints. Survival was assessed using Kaplan–Meier analysis and Cox regression. Results: Both CARWL and NPS significantly stratified OS, PFS, and LRPFS (all p < 0.001). CARWL demonstrated modestly higher discriminatory performance across endpoints. The OS difference between unfavorable and favorable groups was larger with CARWL than with NPS (19.3 vs. 12.3 months). CARWL also provided greater separation for PFS (5.3 vs. 3.2 months) and LRPFS (4.9 vs. 3.4 months). In multivariable analyses, both indices retained independent prognostic significance; however, CARWL consistently exhibited stronger hazard gradients and maintained prognostic value when modeled alongside NPS. Conclusions: Both CARWL and NPS offered meaningful prognostic stratification in stage IIIC NSCLC treated with CCRT, but CARWL demonstrated a modest but more consistent prognostic discrimination than NPS. Pending external validation, CARWL represents a practical and biologically grounded tool for risk stratification in this population.

  • Open Access

    Mandibular Radiation Dose Modifies the Association Between Post-Chemoradiotherapy Dental Extraction Timing and Osteoradionecrosis Risk: A Retrospective Cohort Study

    by Erkan Topkan, Efsun Somay, Sibel Bascil, Duriye Ozturk, Ugur Selek

    Background/Objectives: This retrospective study evaluated whether the association between post-CCRT dental extraction timing and osteoradionecrosis of the jaw (ORNJ) risk is modified by mandibular radiation exposure in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive concurrent chemoradiotherapy (CCRT). Methods: A total of 247 patients who did not undergo pre-CCRT dental extraction but underwent post-CCRT extraction were analyzed. Mandibular radiation exposure was quantified using EQD2. Associations between clinical, tumoral, dental, and dosimetric variables and ORNJ were assessed using multivariable logistic regression, including assessment of EQD2–timing interaction. ROC analyses were performed to evaluate discriminative performance and estimate exploratory thresholds. ORNJ developed in 23 patients (9.3%). Mandibular EQD2 was independently associated with ORNJ risk (OR 2.10 per 5 Gy; 95% CI 1.40–3.15; p < 0.001). A significant interaction between EQD2 and extraction timing was observed (OR 1.07; 95% CI 1.03–1.11; p = 0.023). EQD2 demonstrated excellent discrimination (AUC 0.885; cutoff 46.5 Gy), whereas extraction timing showed modest discrimination (AUC 0.691; cutoff 10 months). At p = 0.012) and hemoglobin level (OR 0.62; p = 0.007) were also independent predictors. Conclusions: The effect of post-CCRT dental extraction timing on ORNJ risk is modified by mandibular radiation dose, supporting interpretation in conjunction with mandibular radiation exposure rather than as an isolated factor.


  • Open Access

    Defining Sarcopenia in Oncology by CT-Based Muscle Mass: The Clinical and Research Consequences of a Diagnostic Surrogate

    by Erkan Topkan, Efsun Somay, Duriye Ozturk, Ugur Selek

    Sarcopenia is increasingly invoked as a determinant of treatment-related toxicity, perioperative morbidity, treatment intolerance, and survival in oncology; however, contemporary international consensus frameworks define sarcopenia as a multidimensional neuromuscular syndrome centered on impaired muscle strength, physical performance, and muscle quality, whereas most oncologic studies operationalize sarcopenia using computed tomography (CT)-derived skeletal muscle mass alone. In this context, muscle quantity is effectively employed as a diagnostic surrogate for a function-centered syndrome. CT-defined skeletal muscle depletion—more precisely described as myopenia—remains a reproducible and clinically informative structural biomarker, yet defining sarcopenia by muscle mass alone aggregates biologically heterogeneous phenotypes, including neuromuscular dysfunction, inflammation-driven cachexia, and substrate-related malnutrition. Such surrogate-based definitions contribute to variable prevalence estimates, inconsistent prognostic associations, and interpretive instability across studies. Clinically, reliance on CT-based muscle mass as a surrogate for sarcopenia may influence chemotherapy dosing, perioperative risk stratification, and supportive care allocation without direct assessment of neuromuscular function; in research settings, mass-based definitions may dilute treatment effects in exercise or nutritional trials and complicate meta-analytic synthesis by conflating structural and functional constructs. This analysis does not question the value of radiologic muscle assessment but argues that CT-derived muscle mass should be recognized as a structural biomarker within a multidimensional framework rather than as a standalone diagnostic surrogate for sarcopenia. A tiered, oncology-adapted approach integrating functional assessment, muscle quality, and relevant metabolic context may enhance risk discrimination, improve trial design, and strengthen translational precision in supportive oncology.


  • Open Access

    The Comprehensive Repair–Inflammation Index (CRII) Predicts Tooth Extraction After Chemoradiotherapy: A Continuous and Nonlinear Modeling Analysis

    by Erkan Topkan, Efsun Somay, Sibel Bascil, Duriye Ozturk, Ugur Selek

    Background: Tooth extraction (TE) after chemoradiotherapy is common in locally advanced nasopharyngeal carcinoma (LA-NPC), yet its determinants remain unclear. We evaluated the association between the Comprehensive Repair–Inflammation Index (CRII), reflecting systemic inflammation and host repair capacity, and TE risk after concurrent chemoradiotherapy (CCRT). Methods: We conducted a retrospective analysis of 354 patients with LA-NPC treated with definitive CCRT. The primary endpoint was post-treatment TE (none vs. ≥1). CRII was calculated from pre-treatment laboratory parameters and analyzed continuously, with a breakpoint identified via segmented regression. Logistic regression and restricted cubic splines were used. Multivariable models adjusted for clinical variables and mandibular dosimetric parameters (mean dose, V50, V60). Results: TE occurred in 70.1% of patients. CRII was significantly higher in those with TE (147.5 vs. 122.0; p < 0.001). CRII was strongly associated with TE (per 10-unit increase: OR 1.49, 95% CI 1.34–1.66; p < 0.001). A nonlinear relationship was observed, with a breakpoint at 145.7, above which TE rates increased markedly (90.5% vs. 58.8%; p < 0.001). CRII remained independently predictive after adjustment (adjusted OR 1.46; ≥145.7: OR 5.1; both p < 0.001). Mandibular dose parameters were not significantly associated with tooth extraction in this analysis. Conclusions: CRII independently predicts post-CCRT TE with a nonlinear risk pattern, highlighting the potential contribution of systemic host-related factors alongside conventional dosimetric parameters.

  • Open Access

    Heat Shock Protein 27 in Radiation-Induced Trismus: Mechanistic Insights and a Hypothesis-Generating Framework

    by Erkan Topkan, Efsun Somay, Doga Topkan, Sukran Senyurek, Duriye Ozturk, Ugur Selek

    Radiation-induced trismus (RIT) is a common and function-limiting late complication of radiotherapy for head and neck cancers, particularly when the masticatory muscles and temporomandibular joint receive high doses. Despite advances in intensity-modulated radiotherapy, RIT remains a significant survivorship problem, and robust biological biomarkers capable of predicting individual susceptibility are lacking. Heat shock protein 27 (HSP27; HSPB1) is a small heat shock protein that regulates multiple cellular stress responses, including proteostasis, cytoskeletal dynamics, redox homeostasis, apoptosis, and inflammatory signaling. In head and neck malignancies, HSP27 overexpression has been associated with treatment resistance and fibrosis-prone tissue remodeling. Experimental studies further demonstrate that HSP27 promotes transforming growth factor-β-mediated myofibroblast differentiation and extracellular matrix deposition, whereas pharmacologic or genetic inhibition attenuates radiation- or bleomycin-induced pulmonary fibrosis in vivo. Evidence from skeletal muscle biology also indicates that HSP27 modulates muscle integrity, denervation-associated atrophy, inflammatory signaling, and cytoskeletal stability. Although HSP27 has been widely investigated in radiation responses, fibrosis, and skeletal muscle stress adaptation, its potential involvement in the pathogenesis of RIT has not been systematically examined. This review proposes a conceptual framework in which HSP27 functions as an integrative molecular mediator linking radiation-induced oxidative stress, endothelial injury, and fibro-atrophic remodeling within the masticatory apparatus. By integrating current evidence on the epidemiology, dosimetric determinants, imaging correlates, and pathophysiology of RIT with the structural and functional biology of HSP27, this review provides the first tissue-specific synthesis of molecular stress signaling and clinical mechanisms relevant to RIT susceptibility. We further suggest that HSP27 signaling may influence susceptibility to fibro-neuromuscular injury in irradiated masticatory tissues. Given the absence of direct experimental or clinical evidence in this setting, these considerations are derived from mechanistic convergence across related biological systems and should be interpreted as biologically plausible but unproven, with potential implications for future biomarker development and biologically informed prevention strategies.


  • Open Access

    A higher number of chemotherapy cycles given during and after radiation is linked to increased rates of radiation-induced trismus in locally advanced nasopharyngeal cancer patients

    by Efsun Somay, Erkan Topkan, Sibel Bascil, Duriye Ozturk, Ugur Selek

    Aim To investigate the impact of the number of chemotherapy cycles (NCTC) on the occurrence of radiation-induced trismus (RIT) in locally advanced nasopharyngeal cancer (LA-NPC) patients who underwent definitive concurrent chemoradiotherapy (CCRT) followed by consolidation chemotherapy. Materials and methods A retrospective analysis was conducted on LA-NPC patients who underwent CCRT between July 2011 and March 2024. The cohort was categorized based on the NCTC (< 3 vs. ≥ 3) and total NCTC (TNCTC: < 4 vs. ≥ 4). The primary objective of this study was to investigate the correlation between the RIT [a maximum mouth opening (MMO) of ≤ 35 mm] incidence and the NCTC and TNCTC parameters. Results A total of 293 patients were included in the study. The incidence of RIT was significantly higher in patients receiving NCTC ≥ 3 (32.5% vs.16.9%; P < 0.001) and TNCTC ≥ 4 (32.4% vs.15.0; P < 0.001). Univariate analysis identified NCTC ≥ 3 (P < 0.001), TNCTC ≥ 4 (P < 0.001), smoking history (P = 0.03), pre-treatment MMO < 41 mm (P = 0.003), and advanced tumor stage (T3-4) (P < 0.001) as independent predictors of RIT. Multivariate analysis revealed that all factors were independent and significant predictors of RIT in this patient group (P < 0.05 for each). Conclusion The findings of this retrospective study indicate that higher NCTC and TNCTC are independently correlated with an increased risk of RIT in LA-NPC patients undergoing CCRT.


  • Open Access

    HCAR score as a prognostic biomarker of survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy

    by Erkan Topkan, Efsun Somay, Duriye Ozturk, Ugur Selek

    Nasopharyngeal carcinoma (NPC) is an aggressive malignancy of the head and neck that is often diagnosed at a locally advanced stage (LANPC). In such cases, intensity-modulated radiotherapy combined with concurrent chemoradiotherapy (CCRT) is the standard treatment; however, the occurrence of distant metastasis and treatment failure remains prevalent. This study evaluates the prognostic significance of a novel composite score that combines hemoglobin levels and the C-reactive protein-to-albumin ratio (HCAR) in LANPC patients undergoing CCRT. We conducted a retrospective analysis of 233 LANPC patients treated with intensity-modulated radiotherapy and platinum-based CCRT from 2011 to 2020. Receiver operating characteristic curve analysis determined pretreatment hemoglobin (Hb) and C-reactive protein-to-albumin ratio (CAR) cut-offs of 11.0 g/dL and 3.0, respectively, which were utilized to create a three-tiered HCAR score: HCAR-0 (Hb ≥11.0 g/dL and CAR <3.0), HCAR-1 (Hb ≥11.0 g/dL and CAR ≥3.0 or Hb <11.0 g/dL and CAR <3.0), and HCAR-2 (Hb <11.0 g/dL and CAR ≥3.0). The primary endpoint of the study was overall survival (OS), while progression-free survival (PFS) was the secondary endpoint. With a median follow-up of 85.7 months, the median PFS and OS were 66.0 months and 108.0 months, respectively, with 5-year PFS and OS rates of 52.8% and 75.9%. The HCAR score significantly stratified patient outcomes: median PFS was not reached for HCAR-0, 66.0 months for HCAR-1, and 25.0 months for HCAR-2. Median OS also varied significantly, being not reached for HCAR-0, 108.0 months for HCAR-1, and 55.0 months for HCAR-2 (all p < 0.001). Corresponding 10-year PFS rates were 50.2%, 34.4%, and 5.0%, while 10-year OS rates were 68.3%, 41.6%, and 11.1%. Multivariate analysis revealed that the HCAR score remained an independent predictor of both PFS and OS, alongside T and N stage. The HCAR score shows promising prognostic utility for predicting OS and PFS in LANPC; however, performance estimates may be overly optimistic due to the lack of internal validation.